VANTABIO.BO Vanta Bioscience BSE up 19.41% pre-market 20 Feb 2026: watch ₹22.99

VANTABIO.BO stock jumped 19.41% in the BSE pre-market on 20 Feb 2026, trading at ₹20.30 up from the previous close of ₹17.00 on light volume of 750 shares. The move places Vanta Bioscience Limited (VANTABIO.BO) among early top gainers in the Healthcare sector in India. The rally follows thin liquidity, a low float and the stock trading below its 50-day average of ₹22.99, creating a short-term battleground between momentum traders and value seekers. We examine fundamentals, technical signals and Meyka AI’s model outlook to frame actionable insights for today’s pre-market session.

VANTABIO.BO stock: price action and quick facts

VANTABIO.BO stock is trading on the BSE at ₹20.30 in pre-market on 20 Feb 2026, a ₹3.30 uptick or 19.41% from the prior close of ₹17.00. Day range shows ₹20.30–₹20.30; year range is ₹16.85–₹33.07. Market cap is ₹144,373,600 with 7,112,000 shares outstanding and average daily volume 3,267. The spike reflects low liquidity (relVolume 0.23) that magnifies intraday moves — check order depth before trading.

VANTABIO.BO stock: fundamentals and valuation snapshot

Vanta Bioscience Limited reports EPS -6.84 and a trailing PE of -2.97, reflecting reported losses. Price-to-book is 0.75, and book value per share is ₹27.06, indicating the market values the company below net equity per share. Debt-to-equity is 1.59, current ratio 0.80, and free cash flow per share is -21.57, signaling cash strain. Revenue per share TTM is 3.13. These ratios point to high operational leverage and weak liquidity despite a modest market cap.

VANTABIO.BO stock: technical picture and trading setup

Technically, VANTABIO.BO shows short-term oversold-to-rebound signs: RSI 33.08, MACD histogram -0.38, and Bollinger middle at ₹20.34 with upper band ₹23.76. The 50-day average is ₹22.99 and 200-day average ₹24.61 — both above the pre-market price, marking resistance. ATR is 1.13, so expect volatile moves. Momentum indicators (CCI -160.26, Stochastic K 18.65) suggest short-covering rallies are possible, but lack of volume (750 vs avg 3,267) warns of shallow follow-through.

VANTABIO.BO stock: Meyka AI grade and analyst framing

Meyka AI rates VANTABIO.BO with a score out of 100: 60.46 (Grade B — HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company rating snapshot shows mixed signals: PB looks attractive at 0.75, but profitability and cash flow metrics are negative. This grade is informational only and is not financial advice.

VANTABIO.BO stock: Meyka AI’s forecast model projects

Meyka AI’s forecast model projects monthly ₹10.91, quarterly ₹8.29, and yearly ₹7.24 versus the current price ₹20.30. That implies model-based downside of -46.26% (monthly), -59.16% (quarterly) and -64.34% (yearly) from today’s level. Forecasts are model-based projections and not guarantees; they reflect historical trends, sector stress and the company’s negative earnings profile.

VANTABIO.BO stock: risks, catalysts and sector context

Key near-term risks include weak cash flow, long operating cycle (days sales outstanding 298, inventory days 590) and high leverage versus sector norms. Healthcare sector averages show stronger profitability and higher PB multiples; Vanta’s valuation disconnect drives both opportunity and risk. Catalysts that could change the picture are better quarterly earnings, contract wins in preclinical services, or a corporate update. Earnings last announced May 2025; check filings for any updates before trading.

Final Thoughts

VANTABIO.BO stock is a classic small-cap, low-liquidity mover in the BSE pre-market on 20 Feb 2026 — ₹20.30 after a 19.41% jump. Fundamentals show negative EPS -6.84, high debt-to-equity 1.59, free cash flow weakness and long working-capital cycles. Technically, short-term buyers can target resistance near the 50-day average ₹22.99 and the Bollinger upper at ₹23.76, with tight risk management given ATR 1.13 and thin volumes. Meyka AI’s forecast model projects lower price levels (monthly ₹10.91, quarterly ₹8.29, yearly ₹7.24), implying significant downside versus today’s price; these projections are model-based and not guarantees. For traders, the stock offers short-term momentum plays but carries material execution and liquidity risk. For investors, the current profile leans toward HOLD with cautious monitoring of cash flow and contract wins. Meyka AI, our AI-powered market analysis platform, flags VANTABIO.BO as speculative and advises confirmatory fundamental news before adding exposure.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.